Categories
Politics

Inventory Trades Reported by Almost a Fifth of Congress Present Potential Conflicts

Despite their influence and extensive access to information, members of Congress can buy and sell stocks with few restrictions.

A New York Times analysis found that 97 lawmakers or their family members bought or sold financial assets over a three-year span in industries that could be affected by their legislative committee work.

Senator Tommy Tuberville, Republican of Alabama and a member of the agriculture committee, regularly reported buying and selling contracts tied to cattle prices starting last year, even as the panel, by Mr. Tuberville’s own account, had “been talking about the cattle markets.”

Representative Bob Gibbs, an Ohio Republican on the House Oversight Committee, reported buying shares of the pharmaceutical company AbbVie in 2020 and 2021, while the committee was investigating AbbVie and five rivals over high drug prices.

The timing of one trade by the wife of Representative Alan Lowenthal, Democrat of California, was especially striking: His disclosure statement said she had sold Boeing shares on March 5, 2020 — one day before a House committee on which he sits released damaging findings on the company’s handling of its 737 Max jet, which was involved in two fatal crashes.

These lawmakers — all of whom defended the transactions as proper — are among 97 current senators or representatives who reported trades by themselves or immediate family members in stocks or other financial assets that intersected with the work of committees on which they serve, according to an extensive analysis of trades from the years 2019 to 2021 by The New York Times.

The potential for conflicts in stock trading by members of Congress — and their choice so far not to impose stricter limits on themselves — has long drawn criticism, especially when particularly blatant cases emerge. But the Times analysis demonstrates the scale of the issue: Over the three-year period, more than 3,700 trades reported by lawmakers from both parties posed potential conflicts between their public responsibilities and private finances.

A selection of stock trading disclosures by members of Congress, with potential conflicts identified by The Times highlighted in yellow.

In some cases, the transactions appear to be routine or to have only a tangential connection to any influence the lawmaker might have had on an issue. In others, the trades were conducted by trusts or brokers who, the lawmakers say, were operating without any instructions or input from them.

But many instances show how legislative work and investment decisions can overlap in ways that at a minimum can leave the appearance of a conflict and that sometimes form a troubling pattern — even if they technically fall within the rules.

Under a 2012 law known as the STOCK Act, members of Congress are allowed to buy and sell stocks, bonds and other financial instruments as long as they do not trade on inside information and disclose any transactions by themselves or immediate family members valued at $1,000 or more within 45 days.

Like everyone else, members of Congress are subject to laws against insider trading. Even knowledge that would fall short of the legal definition of inside information, though, has the potential to create ethical dilemmas for members of Congress who, on any given day, might be able to glean insights through legislative work, classified briefings or meetings with constituents, donors, corporate executives, regulators and other government officials.

Got a confidential news tip?  The New York Times would like to hear from readers who want to share messages and materials with our journalists. Learn more.

Both the House and the Senate have been trying to develop legislation to tighten the rules, but whether a bill will be passed by both chambers and make it to President Biden’s desk this year remains in doubt, despite rare bipartisan support.

“The American people don’t want us day trading for profit, and engaging in active trading of the very equities that are connected to the policies that we are deciding on and voting on every day,” said Representative Chip Roy, a Texas Republican. He is co-sponsoring a bill in the House that would require members to put individual stocks, bonds and many other financial assets in a blind trust, a portfolio that is managed by an outside adviser with no involvement by the owner.

To examine the potential for conflicts, The Times used a comprehensive database called Capitol Trades, which was compiled from congressional trading disclosures by the German financial data firm 2iQ Research.

The Times then matched the trades against committee assignments, hearings and investigations to construct a picture of how members’ congressional work and their personal financial transactions could potentially intersect.

Some committees have broad purview over matters like tax policy, which affects every company and individual in the U.S. economy but which the Times analysis would not have flagged. And members of Congress have wide-ranging influence, and access to sensitive information, that their committee assignments may not reflect.

Yet even with those omissions, the 3,700 potentially conflicted trades identified by the analysis amounted to more than 10 percent of the transactions by members of Congress in the Capitol Trades database during the three years.

The analysis shows that 13 lawmakers, including Mr. Gibbs and other members of the House oversight panel, reported that they or immediate family members had bought or sold shares of companies that were under investigation by their committees between 2019 and 2021, encompassing years in which Democrats controlled the House and control of the Senate swung from Republicans to Democrats.

Bob Gibbs

Representative, R-Ohio

Reported trades in 36 companies;
16 potential conflicts

Oversight Committee

AbbVie*Johnson & JohnsonMerckPfizer

*
Traded while the committee was investigating the company

Oversight Subcommittee on Environment

Exxon MobilAmerican Electric PowerBPEmerson ElectricEnergy TransferEnergy Transfer PartnersMarathon OilMarathon Petroleum

Transportation Committee

BoeingQuantumScapeFordUnion Pacific Corp.

It also showed that 44 of the 50 members of Congress who were most active in the markets bought or sold securities in companies over which their committee assignments could give them some degree of knowledge or influence.

One of the most vexing issues for lawmakers is trading by their immediate family members, some of whom have independent wealth and careers.

The 97 members the Times analysis identified do not include Speaker Nancy Pelosi; her disclosure filings were not flagged because she does not sit on any legislative committees. Her husband, Paul Pelosi, is a real estate and technology investor who reported buying and selling between $25 million and $81 million worth of stocks, options and other financial assets between 2019 and 2021, according to Ms. Pelosi’s filings. Among them were investments in high-profile companies like Alphabet — the parent company of Google — that are regularly the subject of congressional and regulatory scrutiny.

The husband of Representative Carol Miller, Republican of West Virginia, bought shares in the pharmaceutical company AbbVie during the investigation into drug pricing by the House oversight panel while she was serving on the committee, according to Ms. Miller’s disclosure statement.

So did the wife and children of another member of that committee, Representative Ro Khanna, Democrat of California, his filings show. Mr. Khanna’s family members bought or sold shares in not only AbbVie during the committee’s review, but also in those of seven other companies while they were under scrutiny by the oversight panel or other committees on which Mr. Khanna sat.

A page from a stock trading disclosure submitted by Representative Ro Khanna, Democrat of California.

Mr. Khanna, whose wife, Ritu Ahuja Khanna, is the daughter of Monte Ahuja, the founder of a successful automotive equipment company, reported that his wife and children — who are young and whose assets are traded by a trust — bought or sold securities at least 10,500 times in the three-year period The Times studied.

Mr. Khanna said in an interview that he never traded himself and was uninvolved in the trading of his family members’ assets. Mr. Khanna said he favored a complete ban on trading by members, but for family members, he said he thought a “highly diversified trust” that is managed by an outsider — the arrangement used by his wife and young children — was an ethical solution.

“If someone’s coming into a marriage with independent resources, I think that’s the appropriate way to deal with the conflict,” he said.

Ro Khanna

Representative, D-Calif.

Reported trades in 897 companies;
149 potential conflicts

Agriculture Committee

Deere & Co.Mondelez InternationalArcher Daniels MidlandIBMCortevaKelloggKraft HeinzConagra BrandsGeneral MillsFMC Corp.Hormel FoodsSyscoMcCormick & Co.Pilgrim’s PrideSmuckerTyson FoodsCampbell SoupHershey Co.Mosaic Co.US FoodsCF IndustriesLamb WestonPost HoldingsScotts Miracle-Gro

Agriculture Subcommittee on Commodity Exchanges, Energy and Credit

CME GroupIntercontinental Exchange

Agriculture Subcommittee on Livestock and Foreign Agriculture

Idexx LaboratoriesMcDonald’s

Armed Services Committee

AmazonAlphabetBoeingGeneral ElectricOracleBWX TechnologiesHoneywellGeneral DynamicsNorthrop GrummanRaytheon TechnologiesL3Harris TechnologiesRaytheon Co.TeleflexTextronHexcel Corp.Huntington Ingalls IndustriesWoodwardHeico Corp.Howmet AerospaceSpirit AeroSystemsL3 TechnologiesOshkosh Corp.

Armed Services Committee
Oversight Committee

Lockheed Martin*TransDigm

*
Traded during investigation

Armed Services Committee
Oversight Committee
Agriculture Committee

Microsoft

Armed Services Committee
Oversight Subcommittee on Government Operations

Leidos

Oversight Committee

MerckEli LillyWalgreens Boots AllianceAbbVie*Biogen*TwitterAmgen*Vertex PharmaceuticalsBristol Myers SquibbRegeneron PharmaceuticalsAlexion PharmaceuticalsGilead SciencesCapital OneViatrisIncyteAllerganModernaSeagenPerrigoBioMarin PharmaceuticalCelgene*Nektar TherapeuticsJazz PharmaceuticalsCatalentHorizon TherapeuticsAstraZenecaBluebird BioIonis PharmaceuticalsNeurocrine BiosciencesOrganonSage TherapeuticsUnited TherapeuticsAlnylam PharmaceuticalsBioNTechExelixisIntercept PharmaceuticalsNovartis*Ultragenyx

*
Traded during investigation

Oversight Subcommittee on Economic and Consumer Policy

PfizerJohnson & Johnson*Intuitive SurgicalAltria Group*MedtronicPhilip Morris InternationalBecton, Dickinson and CompanyEdwards LifesciencesAbbott LaboratoriesBoston ScientificStrykerAbiomedBaxter InternationalZimmer BiometResMedHologicVarian Medical SystemsCantel MedicalDexcomInogen

*
Traded during investigation

Oversight Subcommittee on Environment

Exxon MobilChevron3M CompanyDominion EnergyEmerson ElectricAmetek Inc.GeneracDuPontPhillips 66Eaton Corp.Nextera EnergyRockwell AutomationSouthern Co.American Electric PowerBaker HughesCMS EnergyConocoPhillipsConsolidated EdisonCoterra EnergyDuke EnergyEOG ResourcesEversource EnergyExelonKinder MorganMarathon PetroleumPioneer Natural ResourcesPublic Service Enterprise GroupSchlumberger Ltd.Sempra EnergySensata TechnologiesValero EnergyWilliams CompaniesXcel EnergyBrookfield InfrastructureBrookfield Renewable Corp.Sunrun

Oversight Subcommittee on Government Operations

VMware

Note: Stock purchases and sales were made by trusts in the names of Mr. Khanna’s wife and young children.

Whether legislators’ privileged position actually yields financial benefits to those who play the markets is not clear. Although some observers have pointed to specific examples of members who appeared to have made a profit, STOCK Act disclosures often provide insufficient information to make that calculation: They show only wide ranges of values, do not have to specify whether a transaction yielded a profit or a loss and sometimes do not show both a purchase and a sale.

But a Dartmouth College study published earlier this year said the specific stocks that members of Congress reported buying and selling between 2012 and 2020 did not, on average, subsequently perform any better or worse than other, similar stocks.

“You cannot rule out that there’s some serious insider trading going on,” said Bruce I. Sacerdote, an economics professor who was a co-author of the study. “What you know for sure is on average they don’t do particularly well, and these House members and senators would be better served if they were just in index funds.”

A Troubling Recent History

Legal and ethical questions about securities trading by members of Congress have surfaced repeatedly in recent years.

In 2020, Senator Richard M. Burr, Republican of North Carolina, was investigated along with three other senators by the Justice Department for selling stocks after a private briefing on the potential harms of the coronavirus. The “well-timed stock sales” allowed Mr. Burr to avert at least $87,000 in losses, according to a recently unsealed affidavit used by the federal government to obtain a search warrant for the senator’s phone in 2020. But charges were never filed and the investigation was eventually closed, as were the investigations into his colleagues. The status of a separate Securities and Exchange Commission review into Mr. Burr is unclear.

A running investigation by the website Insider that began last year reported that 72 members of Congress had fallen out of compliance with the STOCK Act by making trading disclosures late, inaccurately or not at all.

In a rare insider-trading prosecution of a member of Congress, Representative Chris Collins, Republican of New York, resigned in 2019 after pleading guilty to charges related to giving his son insider information about a failed drug trial at an Australian biotech company on whose board the lawmaker served. He served time in prison before being pardoned by President Donald J. Trump.

A Morning Consult poll in January showed that almost two-thirds of respondents would like to see a ban on members of Congress trading.

In the absence of restrictions, Mr. Pelosi’s transactions alone have spawned a cottage industry of social media accounts and trade-tracking services to help investors emulate his market moves — often accompanied by scathing commentary about his wife’s potential conflicts of interest.

“The speaker does not own any stocks,” a spokesman for Ms. Pelosi said, adding that she “has no prior knowledge or subsequent involvement in any transactions.”

Those critiques are fueled by the fact that as speaker, Ms. Pelosi has immense power over which legislation makes it to the House floor — including various proposals now being considered to tighten the rules for financial trading by her husband, her colleagues and their families.

After initially opposing stricter measures, Ms. Pelosi said in February she would support them but wanted federal judges to be held to similar rules. The Wall Street Journal reported last fall that more than 130 federal judges had overseen cases involving companies in which they or their families owned interests.

A bill passed by Congress this year evened out disclosure requirements between the two branches of government. It was signed into law by Mr. Biden in May.

A legislative proposal now under development by the House’s Democratic leadership, which was outlined in a memo reviewed by The Times, would prohibit lawmakers, their spouses and dependent children from trading stocks, bonds, cryptocurrencies and other financial assets tied to specific companies. Under that proposal — which is separate from the bill that Mr. Roy, the Texas Republican, is supporting — members and their immediate families would be obliged to either sell off those holdings or place them in a blind trust.

Ms. Pelosi supports the proposed framework, according to a senior House official.

In the Senate, Chuck Schumer of New York, the majority leader, has voiced support for new measures to curb trading by members, but no bill that could receive the necessary 60 votes for passage has yet emerged.

The House member designated by Ms. Pelosi to generate a compromise bill to address the issue — Representative Zoe Lofgren, Democrat of California — was herself among the 97 members identified by The Times’s analysis.

Zoe Lofgren

Representative, D-Calif.

Reported trades in 127 companies;
9 potential conflicts

Judiciary Committee

PfizerGilead Sciences*MerckAbbVie*Johnson & JohnsonWalgreens Boots Alliance*

*
Bond trades

Judiciary Subcommittee on Courts, Intellectual Property and the Internet

Qualcomm

Science, Space and Technology Committee

Applied MaterialsIntel

Note: Stock purchases and sales were made in accounts owned by Ms. Lofgren’s husband.

Ms. Lofgren ranked 25th among members of Congress for the number of transactions disclosed, as a result of trades made by her husband. Among those were stocks or bonds issued by five drug manufacturers between 2019 and 2021, a period when the House Judiciary Committee, of which Ms. Lofgren has long been a member, introduced multiple bills to lower the cost of prescription drugs and root out what it called anticompetitive practices in the pharmaceutical industry. (Most of the bills never received a vote, although aspects of one proposal were wrapped into a broader spending bill late in 2019.)

Ms. Lofgren said during an April hearing on how to curb congressional stock trading that her husband’s stocks were managed by “some guy at the bank” without the couple’s knowledge. Her office declined to comment on the specifics of the pharmaceutical sales.

“I have never personally purchased or sold any stock,” Ms. Lofgren said in a statement. She added that she and her husband had instructed their broker to avoid fossil fuels, tobacco and gambling companies.

Representative Zoe Lofgren, Democrat of California, has been tasked by the House’s Democratic leadership with generating a compromise bill to address stock trading by members of Congress. Her husband reported trades that intersected with her congressional work.

Erin Schaff/The New York Times

Six members of Congress said that subsequent to making transactions that were flagged by the Times analysis, they or their family members sold all their individual stock investments and stopped buying new ones. Another five members said that they are placing or have placed assets in a blind trust.

One lawmaker, Representative Angie Craig, Democrat of Minnesota, said her son had begun buying and selling a range of stocks without her knowledge while he was at college — much to her chagrin.

A few members said there was nothing wrong with their investing in individual companies.

“I’ve had bank stocks and I’ve been strongly against the banks, and they’ve never supported me, and I’ve got drug stocks and I’ve never supported Big Pharma, and they’ve not supported me, and it’s just irrelevant to me,” said Representative Steve Cohen, Democrat of Tennessee, who added that he had bought some of the stocks decades ago and believed he had not purchased a new share in at least 10 years.

Mr. Cohen said he had deliberately sold Boeing shares only after its price had fallen while it was under investigation for the 737 Max crashes by the Transportation and Infrastructure Committee, of which he is a member, to avoid potential criticism.

In some other professions, the rules are much stricter. Corporate law practices, private equity firms, news organizations and hedge funds restrict the trading of securities that could be affected by knowledge gleaned on the job — even in cases where the employer’s interactions with those companies are far removed from the employee who wants to trade. (The Times does not allow employees to hold stock or any other financial interest in a company or enterprise whose coverage the employee regularly provides or oversees.)

Trading prohibitions are even more stringent in the White House, where officials and staff members must sell off individual stock holdings, recuse themselves from matters that could affect their financial interests or, in rare cases, seek a presidential waiver.

“Every single day we have access to information that people share with us because we’re members of Congress,” said Representative Abigail Spanberger, Democrat of Virginia, whose bill to tighten trading restrictions has attracted 67 co-sponsors from both parties, including Mr. Roy. That information, she said, “can drive markets.”

“And so the whole purpose of this legislation is to say, we have the ability, through this one extra step, to tell the American people that we are trustworthy,” Ms. Spanberger added.

A portrait of Representative Abigail Spanberger, Democrat of Virginia

Representative Abigail Spanberger, Democrat of Virginia, is spearheading a bill to tighten trading restrictions for members of Congress.

Greg Kahn for The New York Times

A portrait of Representative Chip Roy, Republican of Texas

Representative Chip Roy, Republican of Texas, is one of 67 co-sponsors of the bill.

Greg Kahn for The New York Times

Widespread Conflicts

During the three-year period analyzed by The Times, about a third of members of Congress — when all seats are filled there are 535 voting members — bought or sold stocks or other financial assets.

The 97 members who were flagged by the Times analysis amounted to more than half of the people who reported trades, and nearly a fifth of Congress. The group was split almost equally between Democrats and Republicans.

Some committees had multiple members with potential conflicts.

Three members of the House Committee on Financial Services bought or sold Wells Fargo shares during a year in which the committee was investigating the bank’s consumer practices and risk management.

One of them, Representative John W. Rose, Republican of Tennessee, sold between $100,000 and $250,000 worth of the stock late in 2019, a few months before the committee issued a sharply critical report on the company that coincided with a steep decline in the bank’s share price amid pandemic fears. A spokesman for Mr. Rose did not respond to requests for comment.

John W. Rose

Representative, R-Tenn.

Reported trades in 7 companies;
3 potential conflicts

Financial Services Committee

Bank of AmericaPinnacle Financial PartnersWells Fargo

A quarter of the members of the Senate Committee on Energy and Natural Resources reported purchases or sales of securities in energy companies like Exxon and Chevron.

More than a third of the members of the Senate Committee on Environment and Public Works reported either buying or selling stocks like the oil-field services company Schlumberger, the chemical company DuPont or the manufacturer Illinois Tool Works.

In the House, eight members of the Armed Services Committee reported transactions in defense or aerospace stocks.

Some members reported trades in particular companies over and over.

Dr. Deborah Malumed, the wife of Mr. Lowenthal, the California Democrat, bought or sold Sunrun — which installs solar energy systems in homes — on 97 occasions during a yearlong period, according to his disclosure statements. During that time, Sunrun shares experienced two rallies — one that began late in 2019 and extended into early 2020, and a second, much bigger one after a marketwide rout caused by the outbreak of the coronavirus in the United States in March.

Alan Lowenthal

Representative, D-Calif.

Reported trades in 109 companies;
9 potential conflicts

Natural Resources Subcommittee on Energy and Mineral Resources

SunrunVivint SolarSempra EnergyVistraNextera EnergyBrookfield Infrastructure

Transportation Committee

UberBoeingGeneral Motors

Note: The vast majority of stock purchases and sales were made from accounts owned by Mr. Lowenthal’s wife.

In 2020, Mr. Lowenthal, a member of the House Committee on Natural Resources and the chairman of an energy-related subcommittee, was part of a bipartisan group that pushed for the inclusion of renewable energy companies in pandemic relief measures. (Many of the proposals eventually passed last month as part of the Inflation Reduction Act.) In June 2020, he co-sponsored a bill to provide tax incentives for using renewable energy. It never received a vote.

Sunrun shares began rallying around that time; by October they had reached what at the time was a company high of $80. They cost $9 when Dr. Malumed bought shares earlier that year, in March — the month she sold Boeing shares ahead of the Transportation Committee’s preliminary report on the 737 Max jet crashes.

Mr. Lowenthal said in an emailed statement that the “overwhelming majority” of his trades and those of his wife — including the Sunrun and Boeing trades — were made by their stockbroker and without his involvement.

“I have never discussed any congressional matter, including the Boeing 737 Max investigation, with our broker and would never do so,” he said.

Other members traded more broadly within sectors affected by their committees. Mr. Tuberville, a longtime college football coach who joined the Senate in early 2021, quickly established himself as an active trader with recurring potential conflicts.

Senator Tommy Tuberville, Republican of Alabama, at right, reported trades in 20 companies or agricultural commodities that posed potential conflicts, according to the Times analysis.

Stefani Reynolds for The New York Times

As a member of the Senate health committee, he bought and sold shares of major pharmaceutical and medical services companies.

As a member of the Armed Services Committee, on two occasions he and his wife bought, and then in a third transaction sold, options called puts — which represent the right to sell shares at a specified future price — tied to Microsoft in a five-month period. The second put sale occurred less than two weeks before the software company lost a $10 billion contract with the Defense Department. And as a member of the agriculture committee and its subcommittee on commodities, risk management and trade, Mr. Tuberville bet on the future prices of farm products.

Toward the end of 2021, Mr. Tuberville made a flurry of contract purchases tied to future prices of corn and cattle. He continued buying and selling corn and cattle contracts this year, even as the agriculture committee discussed two bills that could affect cattle prices if passed.

Tommy Tuberville

Senator, R-Ala.

Reported trades in 101 companies or commodities;
20 potential conflicts

Agriculture, Nutrition and Forestry Committee

Cattle futuresCorn futuresRed wheat futuresHershey Co.

Armed Services Committee

AlphabetGeneral DynamicsGeneral ElectricHoneywell

Armed Services Committee
Health, Education, Labor and Pensions Committee

Microsoft

Health, Education, Labor and Pensions Committee

ChemedJohnson & JohnsonQuest DiagnosticsAlign TechnologyBecton, Dickinson and CompanyBristol Myers SquibbEdwards LifesciencesMerckRegeneron PharmaceuticalsResMedVeeva Systems

In a brief interview at the Capitol recently, Mr. Tuberville said, “I don’t trade stocks, my brokers do.” He said that he did not receive nonpublic information on the agriculture committee and would never share committee information with his brokers in any case.

“I don’t limit them to anything, what they can do, what they can’t do,” he said. “I give them money, say to them: ‘I’m in public service now; you do it. Don’t lose it all!’”

In recent years, some lawmakers or their families have bought or sold stocks that were likely to be affected by events they had been briefed on confidentially.

Representative Mike Kelly, Republican of Pennsylvania, fell under scrutiny by the Office of Congressional Ethics over a stock trade.

In 2020, Mr. Kelly’s wife, Victoria Kelly, bought $15,000 to $50,000 of stock in the mining company Cleveland-Cliffs — just one day after Mr. Kelly’s office learned that the Commerce Department would initiate a tariff investigation that might benefit the company, which at the time employed about 1,400 workers at a steel plant in Butler, within his congressional district. Mr. Kelly had lobbied Trump administration officials for additional tariff protections, according to an ethics office report.

Ms. Kelly’s purchase — made before the news was public — was the only trade she made in an individual stock that year; records suggest she took a nearly 300 percent profit when she sold eight months later.

The ethics office’s investigation was disclosed last year. While Ms. Kelly’s Cleveland-Cliffs purchase was not flagged by the Times analysis because it did not overlap in an obvious way with her husband’s committee assignments, 23 other transactions made by her in 2019 were purchases and sales of a variety of pharmaceutical, insurance and medical equipment stocks while Mr. Kelly was a member of the health care subcommittee of the House Committee on Ways and Means.

Mr. and Ms. Kelly did not respond to requests for comment, and it is unclear whether the House Committee on Ethics — to which the Office of Congressional Ethics, a separate and independent body, referred the matter last July — is still investigating.

But even ethics committee members in both chambers, who are responsible for ensuring compliance with the STOCK Act disclosure requirements, have potential stock-trading conflicts.

Representative Dean Phillips, Democrat of Minnesota and a member of the House Ethics Committee as well as the Financial Services Committee, traded more than 150 times in tech companies, banks and other financial institutions.

Dean Phillips

Representative, D-Minn.

Reported trades in 276 companies;
34 potential conflicts

Financial Services Committee

Charles SchwabWells FargoBank of New York MellonNorthern TrustGoldman SachsJPMorgan ChaseTruist FinancialE-TradeMetaBank of AmericaCitigroupCitizens FinancialFifth Third BancorpFranklin ResourcesHuntington BancsharesPNC Financial ServicesState StreetComericaFirst Citizens BancsharesInvescoMorgan StanleyAffiliated Managers GroupM&T Bank Corp.PayPalU.S. BancorpCIT Group*CME GroupKeyCorpPeople’s United FinancialRegions Financial Corp.*SVB FinancialSynovus*Wintrust FinancialZions Bancorporation

*
Bond trade

A spokesman for Mr. Phillips said that he “did not direct the sale or purchase of any stocks after being elected” in 2018 “to avoid even the perception of a conflict of interest with his official duties in Congress.” Some of the transactions occurred after January 2020, when the representative said Mr. Phillips began moving most of his stocks into a blind trust, a process that took 18 months.

Representative John Rutherford, Republican of Florida, traded aerospace and defense companies during his time on the House Appropriations Committee’s Subcommittee on Homeland Security. His office did not respond to requests for comment.

John Rutherford

Representative, R-Fla.

Reported trades in 60 companies;
3 potential conflicts

Appropriations Subcommittee on Homeland Security

BAE SystemsMicrosoftLockheed Martin

Mr. Rutherford appeared to be late in reporting more than 150 trades, according to an analysis by the Office of Congressional Ethics, which valued the trades involved at between $652,000 and $3.5 million.

In February, the matter was referred to the House Ethics Committee, of which he is a member.

In August, the committee said it had dismissed the matter.

Kate Kelly covers money, influence, and policy as a correspondent in the Washington bureau of The Times. Before that, she spent 20 years covering Wall Street deals, key players and their intersection with politics. She is the author of three books, including “The Education of Brett Kavanaugh.” @katekelly

Adam Playford is projects editor for The Upshot, where he works on investigative data projects. He previously worked as an investigative editor at the Tampa Bay Times and a reporter at Newsday and the Palm Beach Post. @adamplayford

Alicia Parlapiano is a graphics editor and reporter covering politics and policy from Washington. She joined The Times in 2011 and previously worked at The Washington Post and the Pew Research Center. @aliciaparlap

Ege Uz is a creative technologist and the 2022 Digital News Design Fellow at The Times.

About the analysis

The Times started with data on financial transactions by members of Congress or their immediate family members between 2019 and 2021. The data was drawn from filings by the senators and representatives, which were digitized and connected to data on the companies’ industries by Capitol Trades, a project of the Frankfurt-based financial data company 2iQ Research. The data was compiled by the company’s team of more than 100 analysts, who reviewed each filing by hand, according to Ahmed Asaad, head of research at Capitol Trades, and Diona Denkovska, 2iQ Research’s head of data strategy.

Times reporters built a database of more than 9,000 examples of how those companies intersected with specific congressional committees and subcommittees. They identified committees that oversee areas of federal policy vital to the companies’ business, and those that oversee or fund federal agencies that gave the companies significant contracts. They also looked at investigations that committees have performed into specific corporations and the company leaders whom those committees called to testify in hearings.

They matched those potential conflicts with data on committee assignments, provided by the ProPublica Congress API, Congressional Quarterly and Charles Stewart III, a professor at M.I.T., to find examples of trades that overlapped with the member’s committee tenure.

The Times did not include trades in municipal bonds, mutual funds or index funds, even those that track a specific sector. It also did not consider trades by members who moved quickly to divest from shares shortly after being appointed to a relevant committee or those whose transactions were all sales, as long as they were entirely divesting themselves of stocks within a 60-day period.

The Times could not account for every committee that affects each company; as a result, the analysis is surely an undercount.

Categories
Politics

FTX, Cryptocurrency Chief, Strikes to Curb Excessive Threat Trades

A popular cryptocurrency exchange announced on Sunday that it was curbing some type of high-risk trading, partly due to the sharp fluctuations in the value of Bitcoin and the. is held responsible Casino-like atmosphere on such platforms worldwide.

Switching the exchange, FTX, would reduce the amount of bets investors can place by lowering the leverage offered from 101 to 20 times. Leverage multiplies the trader’s chance not only of profit, but also of loss.

“We will take the first step here,” said Sam Bankman-Fried, 29, the billionaire and founder of the platform, which operates from Hong Kong, on Twitter on Sunday. “Today we are removing the high leverage from FTX. The maximum permissible value will be 20x. “

The announcement came after the New York Times, in an article posted online on Friday, described the risky trades offered on FTX and other global exchanges such as Binance and BitMEX that accelerated a global crash in May. This month, those bets worth more than $ 20 billion were liquidated on cryptocurrency exchanges around the world.

Bankman-Fried said lowering leverage “is a step in the direction the industry has been headed and has been for a while,” adding, “Although we believe many of the arguments in favor of With high leverage, we don’t miss the mark either, believing it’s an important part of the crypto ecosystem, and in some cases it’s not a healthy part of it. “

Global platforms like FTX allow traders to borrow big when betting on price fluctuations – traders don’t buy and sell cryptocurrencies, but instead predict where the prices of the underlying assets will go. These bets, known as derivatives, mean that the exchange will grant them credit when they raise $ 1,000 so they can wager on the future price of the cryptocurrency worth up to $ 101,000 on FTX. Now, with the new cap, the maximum on this transaction would be $ 20,000.

This type of transaction should not be available to professional investors in the United States, but – at least historically – some of these investors have used workarounds to trade on the sites.

Leverage makes investors much more susceptible to their accounts being liquidated due to an automated margin call if the price of the cryptocurrency goes against their prediction and they do not have enough collateral on their accounts to support their bets.

It happened in May. When cryptocurrency prices began to fall due to market-moving events such as China’s announcement of regulatory action or Tesla’s decision to suspend Bitcoin payments, it prompted exchanges to automatically liquidate the accounts of the most leveraged investors before their collateral were no longer sufficient to cover their positions.

“These liquidations are obviously a big factor in the price crash,” said Clara Medalie, head of research at Kaiko, a provider of cryptocurrency market data in Paris, and recalled the sudden fall in value of the cryptocurrency in mid-May. “It is a doom-loop.”

Bankman-Fried said on Sunday that only a small percentage of traders are taking advantage of the maximum leverage available. He also argued that FTX had fewer liquidations than other exchanges and that he had long sought to “promote responsible trading”.

Still, he predicted in an interview last week that some investors would not welcome a move to reduce debt. “We’d get a consumer outcry if we got rid of it and we’d get very bad press,” he said. “But it could be the right thing.”

Mr Bankman-Fried also admitted that high leverage created the impression that exchanges like him were promoting risky trading, although he claimed it was not a fair conclusion.

Binance, the world’s largest cryptocurrency exchange, offers up to 125x leverage. Changpeng Zhao, the Sino-Canadian founder of Binance and a developer who traces his professional roots back to Wall Street, has said that the extreme leverage numbers were just a “marketing gimmick” and that most traders don’t use them.

Timothy Massad, the former chairman of the Commodity Futures Trading Commission, which regulates derivatives in the U.S., said he welcomed FTX’s decision and hoped other platforms like Binance would follow suit.

The change, he said, could be motivated in part by FTX’s success last week in raising $ 900 million in venture capital, the highest ever value for a cryptocurrency exchange. FTX’s high leverage offerings are more likely to damage its reputation as Mr Bankman-Fried seeks to expand the global reach of its platform, Mr Massad said.

“Sam has bigger visions, and this step removes a focus that might be in the way,” said Massad. “Take it off the table.”

Categories
Health

Gene testing agency 23andMe trades increased after Branson SPAC merger

Anne Wojcicki, co-founder and CEO of 23andMe (right) celebrates with 23andMe employees after remotely ringing the NASDAQ opening bell at the headquarters of DNA technology company 23andMe in Sunnyvale, California, USA on June 17, 2021.

Peter DaSilva | Reuters

The newest trade on the exchange is “ME”.

23andMe, a personalized medicine and home genetic test kit company, went public on Thursday through a merger with a Richard Branson SPAC, VG Acquisition Corp..

23andMe stock rose 21% on the Nasdaq on its first day of trading as a publicly traded company.

Founded by Anne Wojcicki – the former wife of Google founder Sergey Brin who was an early investor in the company – 23andMe was founded 15 years ago. Together with Ancestry, it helped advance the idea that genetic testing is not just a medical field, but a big consumer business. His home test kits, which enabled people to find out their genetic profiles and ancestry by sending some saliva in the mail, ushered in a new era of personalized medicine, albeit not without controversy.

23andMe, a five-time CNBC Disruptor 50 company, had no straight or sure path to success as a publicly traded company.

It was reviewed by the FDA earlier in its history; Questions about consumer privacy continue to arise as genetic information is collected from millions of people; has run into financial difficulties in recent years when the market for personalized genetic testing seemed saturated; Skepticism about the basis of their gene-based risk analysis remains controversial; and as it delves deeper into drug development, a gap in its current customer base and underlying genetic data between a mostly European genetic profile and an underrepresentation of many minorities and ethnic groups.

“It will take time … to really make sure we get all communities to participate in the research,” Wojcicki said Thursday morning in an interview with CNBC’s TechCheck. “You can’t make discoveries in a population if those people aren’t part of it. We need the right customers and we have to present the product to them in the right way.”

Wojcicki says the company has big things ahead of it for both its consumer and drug discovery and development platforms. Approximately 80% of 23andMe’s 11 million members now choose to share their genetic information (anonymized) for drug development research.

“Our genetics represent all of life on this planet and we have the opportunity to understand what it means and, in doing so, it will improve your own life, but it will also contribute to all kinds of research discoveries,” said Wojcicki.

She says the controversy over the medical usefulness of the information won’t go away once it is put into the hands of consumers, and it ranges from critical, clinical information such as mutations in the gene that causes breast cancer, BRCA, to “more controversial” genetic ones Information on variants of Alzheimer’s disease. Some people at higher risk of blood clots choose to walk around more during flights based on their 23andMe reports.

However, she added that consumers have shown that they want this information to help them make decisions.

In the case of Alzheimer’s risk, she said, “This information … really affects how they live their lives … how they retire … plan to get older.”

Her own 10-year-old son used the company’s lactose intolerance analysis to diagnose his abdominal pain, and Wojcicki herself said, although she was reluctant to talk about her personal use of the product, as the daughter of a woman who suffered from breast cancer and who a higher risk of illness, the information influences their decision to drink that “leisure glass of wine”.

“Over the past 15 years we’ve built the infrastructure so we can take off to prove to consumers that we can get the information and understand it without a healthcare professional,” she said.

In her opinion, the key to the future is that consumers want to use the information not only to change their lives, but also to contribute to drug discovery.

23andMe has 40 programs ongoing on its drug discovery platform.

“We want them to have a truly personalized health experience and … benefit the human genome when all of this aggregated data is turned into therapeutic programs,” said Wojcicki. “When I think about the future of therapeutics, the next five years are really about moving these programs forward and getting them into the clinic.”

The company also recently launched a subscription product to bring more content and services to consumers who want to take extra steps after their genetic reports.

“We reach thousands of people who call the customer care team each week and want to know how this information can be used and applied to lead healthier longer lives,” she said.

The IPO market already set an annual record for the transaction volume of $ 171 billion in 2021, and only halfway through the year. Average first day trading profits on trades this year were over 40%. Although both the traditional IPO market and SPAC yields have cooled in recent months, the Renaissance IPO ETF and CNBC SPAC Index have been negative since the start of 2021, with a continuation of last year’s big gains since the start of the year. Meanwhile, concerns about SPAC deals have increased, and some high profile SPACs like Branson’s Virgin Galactic and electric vehicle maker Lordstown Motors have shown high levels of volatility.

Nonetheless, Branson and other investors plan to bring another space company, the satellite internet service Virgin Orbit, to the public via a SPAC in the coming weeks.

This history has been updated for the company’s closing price on the first day of trading on Thursday.

SIGN IN for our weekly original newsletter that goes beyond the list and offers a closer look at CNBC Disruptor 50’s companies and the founders who continue to innovate in all areas of the economy.

Categories
World News

Shares drift larger at open, S&P 500 trades just below report

The S&P 500 was just below its all-time high on Wednesday as markets continued to trade in a tight range.

The 500 stock index rose 0.2%, hitting one point off its intraday record within the first two minutes of the regular trading session. The S&P 500 is now just 0.15% below its record high of 4,238.04 May 7th. The Nasdaq Composite was up 0.5% and the Dow Jones Industrial Average held steady around Tuesday’s closing prices.

Health, communications and technology stocks drove the positive readings, with drug maker Merck up 1.8%, Twitter 1.7% and Adobe 1.5%. Fox Corp. was the best performer in the S&P 500 with a plus of 2.3%.

The meme stock mania continued Wednesday, with day traders now turning their attention to Clover Health. The stock gained another 12% before tumbling after an 85% rally on Tuesday amid explosive trading volumes. Clean Energy Fuels rose 30% on Wednesday with no apparent news.

Investors wait for the next inflation measurement to assess whether the higher price pressures are temporary as the economy continues to recover from the pandemic-induced recession.

“US stocks have been largely stuck in a range since mid-April and are unlikely to break out anytime soon,” said Edward Moya, senior market analyst at Oanda, in a press release. “Investors want to see how hot the price pressures will get and how much downtrend in stocks will happen once the Fed’s taper rage begins.”

The consumer price index for May is due to be published on Thursday. According to the Dow Jones, economists expect the consumer price index to increase by 4.7% year-on-year. In April the CPI rose 4.2% on an annual basis, the fastest increase since 2008.

Many on Wall Street believe the latest meme stock episode should be limited to a handful of names, in contrast to the GameStop trading frenzy in January that affected the broader stock market.

“Given the low risk of widespread contagion, we see the consequences of the recent short squeeze as
“Maneesh Deshpande, Global Head of Equity Derivatives Strategy at Barclays, said in a press release.” The current short squeeze is likely to be more localized because the number of stocks with high short interests has decreased dramatically.

On the data front, job vacancies rose to a new record high in April, with 9.3 million jobs posted online as the economy recovered.

– CNBC’s Tom Franck contributed to this story.

Categories
World News

Nasdaq falls greater than 1% as tech sell-off continues, Dow trades off low on Powell

Tech stocks led the broader market down for a second day on Tuesday, amid higher interest rates and a rotation in stocks more linked to the economic rebound.

The Nasdaq Composite fell 1.4% for the first time since November 3, falling below its 50-day moving average, a key technical indicator. The S&P 500 fell 0.4% while the Dow Jones Industrial Average fell 70 points to its lows after 360 points.

Stocks rebounded from their lows after Federal Reserve Chairman Jerome Powell told Congress in his testimony that inflation is still “weak” and the economic outlook is still “highly uncertain”, which is what concerns a change in policy by the central bank.

“The economy is far from our employment and inflation targets, and it will likely take some time to make significant further progress,” said the Fed chief in prepared remarks for the Senate Banking Committee.

Fears of inflation have risen in recent weeks amid a sharp rise in bond yields as policy makers debated another round of economic relief. Investors fear that a price hike due to government incentives could force the central bank to raise short-term borrowing costs.

“The Fed is focused on employment and appears very poised to absorb higher inflation and excesses in the financial market, creating financial instability in hopes of getting there,” said Peter Boockvar, chief investment officer of the Bleakley Advisory Group , in a note. “But as can be seen at the long end of the yield curve, the markets have a say in this too and speak loudly. Hopefully the Fed officials will listen at some point.”

Tech stocks, the most vulnerable to higher interest rates, have sold out in the past few days. Investors also rushed to book profits on these pandemic winners, whose valuations have reached historically high levels.

Tesla was trading 4% lower after previously falling 13% after falling 9% in the previous session. Apple lost 1.7% after falling 3% on Monday. The iPhone maker’s stock is down about 11% over the past month.

Small caps also came under pressure as the Russell 2000 fell 1.9% on Tuesday and rose 6.5% in February. Those shabby value shares outpaced the S&P 500 in 2021 amid optimism about the vaccine launch and economic reopening.

“The sell-off of tech darlings and popular small caps could be interpreted as the beginning of market volatility,” said Chris Larkin, chief executive officer for trading and investing products at E-Trade. “It’s not to say that stocks have run their course, it’s more that cyclical sectors like energy and finance are more attractive as technology takes a back seat.”

The 10-year government bond yield, which has been rising steadily since early 2021, remained steady at 1.36% on Tuesday. So far this month the key rate has risen by an impressive 28 basis points. The 30-year yield hit a year-high of 2.2% on Monday. One basis point is 0.01%.

The losses incurred during Tuesday’s session contributed to growing divergence between key areas of the market. The tech-heavy Nasdaq Composite, which fell 2.5% on Monday, is down about 4% this week.

The Dow, which comprises a larger proportion of cyclical stocks, is down a far more modest 0.1% since Friday’s close as investors pick up names they believe will benefit from an economic rebound. Energy and finance – two of the best performing sectors this year – again supported the market on Tuesday.

Jonathan Golub, chief strategist at Credit Suisse in the US, believes cyclical stocks will take the market to new highs as the year progresses, driven by the upside in earnings and optimism about the economic reopening.

“Rising interest rates – a benefit to finance – and copper and oil prices – a boon to industry, energy and materials – further reinforce this favorable backdrop,” Golub said in a statement on Tuesday.

Credit Suisse increased its S&P 500 year-end target from 4,200 to 4,300. The new forecast corresponds to an 11.5% rally.